Findlay Park Partners LLP bought a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 171,902 shares of the medical instruments supplier’s stock, valued at approximately $40,457,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Moors & Cabot Inc. bought a new stake in West Pharmaceutical Services in the 4th quarter worth approximately $257,000. McCollum Christoferson Group LLC boosted its holdings in shares of West Pharmaceutical Services by 0.5% in the 4th quarter. McCollum Christoferson Group LLC now owns 49,980 shares of the medical instruments supplier’s stock worth $11,763,000 after purchasing an additional 271 shares during the period. Daiwa Securities Group Inc. boosted its holdings in shares of West Pharmaceutical Services by 17.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 5,810 shares of the medical instruments supplier’s stock worth $1,367,000 after purchasing an additional 846 shares during the period. Settian Capital LP boosted its holdings in shares of West Pharmaceutical Services by 10.9% in the 4th quarter. Settian Capital LP now owns 6,100 shares of the medical instruments supplier’s stock worth $1,436,000 after purchasing an additional 600 shares during the period. Finally, Fiducient Advisors LLC purchased a new position in shares of West Pharmaceutical Services in the 4th quarter worth approximately $964,000. Institutional investors own 91.51% of the company’s stock.
Analysts Set New Price Targets
WST has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft boosted their price objective on West Pharmaceutical Services from $250.00 to $290.00 in a report on Wednesday, February 22nd. StockNews.com began coverage on West Pharmaceutical Services in a research note on Thursday, May 18th. They set a “hold” rating for the company. KeyCorp upped their price objective on West Pharmaceutical Services from $315.00 to $375.00 and gave the stock an “overweight” rating in a research note on Friday, February 17th. Finally, Stephens upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $330.00 to $400.00 in a research note on Tuesday, April 11th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, West Pharmaceutical Services currently has an average rating of “Hold” and a consensus price target of $313.00.
Insider Buying and Selling
West Pharmaceutical Services Stock Down 2.3 %
West Pharmaceutical Services stock opened at $342.81 on Wednesday. The firm has a market cap of $25.45 billion, a price-to-earnings ratio of 47.09, a price-to-earnings-growth ratio of 7.29 and a beta of 1.09. West Pharmaceutical Services, Inc. has a 52 week low of $206.19 and a 52 week high of $376.72. The business’s 50-day moving average price is $352.19 and its 200 day moving average price is $292.55. The company has a quick ratio of 2.79, a current ratio of 3.62 and a debt-to-equity ratio of 0.07.
West Pharmaceutical Services (NYSE:WST – Get Rating) last posted its earnings results on Thursday, April 27th. The medical instruments supplier reported $1.98 EPS for the quarter, topping the consensus estimate of $1.67 by $0.31. West Pharmaceutical Services had a return on equity of 24.14% and a net margin of 19.15%. The firm had revenue of $716.60 million for the quarter, compared to analyst estimates of $697.28 million. During the same period last year, the company earned $2.30 earnings per share. West Pharmaceutical Services’s revenue for the quarter was down .5% compared to the same quarter last year. As a group, sell-side analysts anticipate that West Pharmaceutical Services, Inc. will post 7.63 earnings per share for the current year.
West Pharmaceutical Services Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 2nd. Stockholders of record on Wednesday, July 26th will be paid a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.22%. The ex-dividend date of this dividend is Tuesday, July 25th. West Pharmaceutical Services’s dividend payout ratio is presently 10.44%.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers.
- Get a free copy of the StockNews.com research report on West Pharmaceutical Services (WST)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.